Incidence of Second Malignancy in Patients with Papillary Thyroid Cancer from Surveillance, Epidemiology, and End Results 13 Dataset

Table 4

Frequency and standardized incidence ratio of SPM by gender and year of diagnosis.

Site	Year and gender
	1992–1999/		1992–1999/		1992–1999/		2000–2012/		2000–2012/		2000–2012/
	male and female		male		female		male and female		male		female
	Observed	O/E	Observed	O/E	Observed	O/E	Observed	O/E	Observed	O/E	Observed	O/E
All sites	1,408	1.10#	438	1.16#	970	1.08#	1689	1.24#	547	1.41#	1142	1.17#
All solid tumors	1,240	1.08#	380	1.13#	860	1.06	1500	1.22#	462	1.34#	1038	1.18#
Oral cavity and pharynx	36	1.41	15	1.26	21	1.53	45	1.64#	20	1.55	25	1.71#
Colon and rectum	108	0.89	36	0.95	72	0.86	120	1	36	0.99	84	1.01
Rectum and rectosigmoid junction	19	0.54#	7	0.57	12	0.53#	32	0.9	13	1.08	19	0.81
Respiratory	119	0.75#	39	0.70#	80	0.77#	165	1.03	48	0.92	117	1.09
Lung and bronchus	116	0.77#	38	0.76	78	0.78#	164	1.09	47	1	117	1.13
Skin	72	1.22	29	1.47	43	1.1	100	1.48#	38	1.68#	62	1.38#
Melanoma	67	1.24	26	1.44	41	1.14	92	1.47#	35	1.68#	57	1.36#
Breast	348	1.14#	1	1.24	347	1.14#	376	1.15#	2	2.29	374	1.15#
Prostate	162	1.35#	162	1.35#	0	0	169	1.41#	169	1.41#	0	0
Kidney and renal pelvis	57	1.73#	21	1.58	36	1.83#	105	2.71#	42	2.71#	63	2.71#
Kidney	56	1.82#	21	1.69#	35	1.91#	104	2.84#	42	2.87#	62	2.82#
Brain and other nervous system	14	0.94	5	1.06	9	0.89	25	1.57#	6	1.2	19	1.74#
Endocrine system	48	1.22	9	2.23#	39	1.11	79	1.48#	20	3.79#	59	1.23
All lymphatic and hematopoietic diseases	142	1.41#	48	1.42#	94	1.41#	151	1.39#	65	1.81#	86	1.18
Lymphoma	67	1.19	21	1.17	46	1.2	72	1.19	33	1.72#	39	0.94
Hodgkin lymphoma	6	1.15	0	0	6	1.6	5	0.87	4	2.49	1	0.24
Non-Hodgkin lymphoma	61	1.19	21	1.27	40	1.16	67	1.22	29	1.65#	38	1.02
Myeloma	27	1.82#	8	1.58	19	1.94#	19	1.16	10	1.81	9	0.82
Leukemia	48	1.64#	19	1.79#	29	1.56#	60	1.91#	22	1.95#	38	1.88#

#: .